pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
GRAALL2014
Phase 2 · other · Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
GRAALL2014 for Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years) is a Phase 2 program (other) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 2
- Modality
- other
- Indication
- Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
- Status
- active
- Trials
- 1